Paolo Calabresi

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 380 publications

Is continuous dopaminergic delivery still a major goal to be achieved in the treatment of Parkinson's disease?

Is continuous dopaminergic delivery still a major goal to be achieved in the treatment of Parkinson's disease?

Journal: Journal of Parkinson's disease

Published: July 10, 2026

Long-lasting concordance between imaging-guided and clinical-based STN-DBS programming enhances motor and axial outcomes in Parkinson's disease: A 3-year single-center study.

Long-lasting concordance between imaging-guided and clinical-based STN-DBS programming enhances motor and axial outcomes in Parkinson's disease: A 3-year single-center study.

Journal: Journal of Parkinson's disease

Published: July 07, 2026

SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study).

SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study).

Journal: Cephalalgia : an international journal of headache

Published: June 26, 2026

External Validation of Published Scoring Systems to Predict Incident Atrial Fibrillation After Cryptogenic Stroke/Embolic Stroke of Undetermined Source.

External Validation of Published Scoring Systems to Predict Incident Atrial Fibrillation After Cryptogenic Stroke/Embolic Stroke of Undetermined Source.

Journal: Journal of the American Heart Association

Published: June 23, 2026

CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment.

CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment.

Journal: Cephalalgia : an international journal of headache

Published: June 17, 2026

Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.

Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.

Journal: The journal of headache and pain

Published: May 10, 2026

Post-pipeline headache after flow-diverting stenting for unruptured intracranial aneurysms: clinical, radiological findings, and proposed scoring system.

Post-pipeline headache after flow-diverting stenting for unruptured intracranial aneurysms: clinical, radiological findings, and proposed scoring system.

Journal: Journal of neurology

Published: April 21, 2026

The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability.

The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability.

Journal: Cephalalgia : an international journal of headache

Published: March 25, 2026

Serum peripherin as a disease biomarker in hereditary transthyretin amyloidosis: a multicenter cohort study.

Serum peripherin as a disease biomarker in hereditary transthyretin amyloidosis: a multicenter cohort study.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: March 16, 2026

Awareness, attitudes, and clinical practices related to medication-overuse headache among Italian pharmacists: results from a cross-sectional survey.

Awareness, attitudes, and clinical practices related to medication-overuse headache among Italian pharmacists: results from a cross-sectional survey.

Journal: The journal of headache and pain

Published: February 25, 2026

Cenobamate use in super-refractory status epilepticus: A report of three cases.

Cenobamate use in super-refractory status epilepticus: A report of three cases.

Journal: Epileptic disorders : international epilepsy journal with videotape

Published: February 19, 2026

Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study).

Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study).

Journal: Cephalalgia : an international journal of headache

Published: February 13, 2026

Showing 1-12 of 380

Last Updated: 09/26/2026